Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$15.19
$8.13
$26.28
$24.33M0.4124,454 shs237,144 shs
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$9.09
+17.4%
$6.30
$1.72
$10.40
$33.18M1.38132,457 shs76,079 shs
Soligenix, Inc. stock logo
SNGX
Soligenix
$1.93
+1.0%
$2.01
$1.68
$14.83
$6.30M2.06760,607 shs12,277 shs
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
$6.30
+1.9%
$7.55
$5.35
$47.45
$23.20M-1.78159,282 shs21,023 shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
0.00%0.00%0.00%+6.40%-33.95%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
+13.66%+20.19%+15.35%-4.91%+309.89%
Soligenix, Inc. stock logo
SNGX
Soligenix
+5.52%-3.05%-11.98%-16.23%-67.29%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-0.80%-7.76%-20.36%-42.53%-85.37%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
1.5877 of 5 stars
3.00.00.04.20.00.80.0
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.6024 of 5 stars
0.05.00.00.02.20.00.0
Soligenix, Inc. stock logo
SNGX
Soligenix
1.0036 of 5 stars
0.05.00.00.01.50.01.3
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
1.8044 of 5 stars
3.34.00.00.01.50.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
2.00
Hold$36.00∞ Upside
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.00
N/AN/AN/A
Soligenix, Inc. stock logo
SNGX
Soligenix
0.00
N/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
2.50
Moderate Buy$30.00376.19% Upside

Current Analyst Ratings Breakdown

Latest SNGX, TPST, CARA, and PULM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$16.00 ➝ $16.00
4/10/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Outperform ➝ Sector Perform$7.00 ➝ $9.00
3/28/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$169.00 ➝ $91.00
3/28/2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$611.00 ➝ $208.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
$7.14M0.00N/AN/A$12.58 per share0.00
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
$1.92M17.27N/AN/A$4.93 per share1.84
Soligenix, Inc. stock logo
SNGX
Soligenix
-$117.03K-53.83N/AN/A$3.83 per share0.50
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/A$1.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
-$118.51M-$21.01N/AN/AN/A-1,099.76%-367.97%-107.43%N/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
-$14.12M-$3.34N/AN/A-96.51%-45.97%-30.72%8/11/2025 (Estimated)
Soligenix, Inc. stock logo
SNGX
Soligenix
-$6.14M-$4.29N/AN/AN/A-1,473.38%-223.29%-74.18%8/8/2025 (Estimated)
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$29.49M-$17.98N/AN/AN/AN/A-187.44%-82.61%8/14/2025 (Estimated)

Latest SNGX, TPST, CARA, and PULM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.50N/A-$0.50N/AN/A
5/13/2025Q1 2025
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.71-$3.16+$0.55-$3.16N/AN/A
5/9/2025Q1 2025
Soligenix, Inc. stock logo
SNGX
Soligenix
-$0.67-$1.06-$0.39-$1.06N/AN/A
3/27/2025Q4 2024
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
-$3.12-$4.03-$0.91-$0.31N/A$0.49 million
3/21/2025Q4 2024
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A-$0.54N/A-$0.54N/AN/A
3/21/2025Q4 2024
Soligenix, Inc. stock logo
SNGX
Soligenix
-$0.95-$1.14-$0.19-$1.14$0.20 million$0.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/AN/AN/AN/AN/A
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/AN/AN/AN/AN/A
Soligenix, Inc. stock logo
SNGX
Soligenix
N/AN/AN/AN/AN/A
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
N/A
4.77
4.71
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
N/A
19.40
19.40
Soligenix, Inc. stock logo
SNGX
Soligenix
N/A
2.28
2.28
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
N/A
1.69
1.69

Institutional Ownership

CompanyInstitutional Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
44.66%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
11.84%
Soligenix, Inc. stock logo
SNGX
Soligenix
3.60%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
22.52%

Insider Ownership

CompanyInsider Ownership
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
3.10%
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
0.62%
Soligenix, Inc. stock logo
SNGX
Soligenix
3.05%
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
4.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cara Therapeutics, Inc. stock logo
CARA
Cara Therapeutics
804.57 million4.43 millionOptionable
Pulmatrix, Inc. stock logo
PULM
Pulmatrix
203.65 million3.63 millionNot Optionable
Soligenix, Inc. stock logo
SNGX
Soligenix
203.26 million2.44 millionNot Optionable
Tempest Therapeutics, Inc. stock logo
TPST
Tempest Therapeutics
203.68 million41.59 millionOptionable

Recent News About These Companies

Q2 EPS Estimate for Tempest Therapeutics Raised by Analyst
Tempest Therapeutics
Tempest Therapeutics announces FDA granted ODD to TPST-1495

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cara Therapeutics stock logo

Cara Therapeutics NASDAQ:CARA

Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Pulmatrix stock logo

Pulmatrix NASDAQ:PULM

$9.09 +1.35 (+17.44%)
Closing price 04:00 PM Eastern
Extended Trading
$9.20 +0.11 (+1.20%)
As of 05:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Soligenix stock logo

Soligenix NASDAQ:SNGX

$1.93 +0.02 (+1.05%)
Closing price 03:59 PM Eastern
Extended Trading
$1.92 -0.01 (-0.52%)
As of 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Tempest Therapeutics stock logo

Tempest Therapeutics NASDAQ:TPST

$6.30 +0.12 (+1.94%)
Closing price 04:00 PM Eastern
Extended Trading
$6.46 +0.16 (+2.46%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors. It also develops TREX-1, an enzyme that regulates cGAS/STING pathway signaling and immune recognition. Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.